IL17A and inflammatory bowel disease: Cessation of IL-17-mediated inflammation through IL-17 inhibitors was expected to be found, in theory, in inflammatory bowel disease as well; however, nowadays, multiple studies demonstrate the contrary [50,54,55,56].